The critical role of eosinophils in EGPA is well established, as demonstrated by the clinical benefit of eosinophil-targeted anti-interleukin-5 (anti-IL-5) antibody therapy (52, 53). This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.